- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears Enhanced 3D Ultrasound Platform for Thyroid Imaging
The Piur tUS Infinity system reportedly reduces operator dependency with ultrasound through upgrading of two-dimensional ultrasound devices and access to 3D multiplanar image reconstructions of thyroid conditions.
Offering an ultrasound platform that may have the capability to upgrade two-dimensional (2D) ultrasound devices with access to three-dimensional (3D) views of thyroid conditions, the Piur tUS Infinity system has garnered 510(k) clearance from the Food and Drug Administration (FDA).
The Piur tUS Infinity platform enables clinicians to obtain multiplanar reconstructions from a single sweep with a traditional 2D ultrasound device, according to Piur Imaging, the developer of Piur tUS Infinity.
The newly FDA-cleared Piur tUS Infinity platform enables clinicians to obtain 3D multiplanar reconstructions from a single sweep with a traditional 2D ultrasound device, according to Piur Imaging, the developer of Piur tUS Infinity. (Image courtesy of Piur Imaging.)
Providing detailed volumetric assessment of thyroid lobes and nodules with a single scan, Piur Imaging said the Piur tUS Infinity platform facilitates nodule classification with the Thyroid Imaging Reporting and Data System (TI-RADS). The company added that the Piur tUS Infinity platform facilitates standardized reporting for PACS systems, and use of the 3D system may be reimbursed via CPT Category I code 76377.
“This technology offers an enhanced view into thyroid conditions, enabling clinicians to make more informed, precise decisions in patient care,” noted Frederik Bender, the chief executive officer of Piur Imaging.
Multicenter Study Shows Merits of AI-Powered Ultrasound Assessment for Detecting Ovarian Cancer
January 3rd 2025Adjunctive AI offered greater than seven percent increases in sensitivity, specificity, and accuracy for ultrasound detection of ovarian cancer in comparison to unassisted clinicians who lacked ultrasound expertise, according to findings from new international multicenter research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
